- ECONOMIC IMPACT -

Latest update: 15 September 

The global economy is forecasted to return to pre-crisis levels by the end of 2021 or early 2022. 

According to Statistics South Africa, real GDP in the nation expanded by 1.2% in Q2 2021.

6.2%

The unemployment rate in OECD nations stood at 6.2% in July 2021, down from 6.4% in June 2021.

4.5%

World economic growth is projected at 5.7% in 2021 and at 4.5% in 2022, according to HIS Markit.

Impact of Covid-19 on equity indices

- SECTOR IMPACT: PHARMA -

Latest update: 08 October

industry development

5,941

Currently, there are 5,941 clinical trials for Covid-19 and promising clinical data continues to emerge for Covid-19 vaccines. 

1,058

Trial disruption is levelling off, with 1,058 trials still disrupted and 628 pharma/biotech companies and clinical research organisations associated with disrupted trials.

Outsourcers (CROs/CMOs)

Stalled clinical trials created a work vacuum for clinical research organisations (CROs) and contract development and manufacturing organisations but disrupted trials are slowly starting to resume.


Contract manufacturing organisations (CMOs) and excess capacity contract manufacturers with secure supply lines will benefit from a short term boost in generic drugs manufacturing needed to treat Covid-19 patients.


Outsourcing partners must deal with issues surrounding a potential excess of client needs upon initiation of future trials, with guidance from regulatory agencies still pending.

Key pharma market developments

Share this article

Go to article: Home | Unpacking innovation in biologics Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: Verder Company InsightGo to article: VerderGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Controlant Company InsightGo to article: ControlantGo to article: DatwylerGo to article: BaxterGo to article: CommentGo to article: Novel therapies will drive Cushing’s syndrome market growthGo to article: Interim analysis backs Keytruda use in first-line cervical cancer therapy Go to article: Unmet needs and opportunities for axillary hyperhidrosisGo to article: Pfeiffer VacuumGo to article: HOF SonderanlagenbauGo to article: Avery Dennison Company Insight Go to article: Avery DennisonGo to article: In DepthGo to article: The reality of optimising real-world data Go to article: The ethics of vaccine boostersGo to article: Forever young: can science cure ageing? Go to article: Predicting the placebo responseGo to article: US regulators struggle to keep up with a global marketGo to article: BCG: the history and modern-day uses of the tuberculosis vaccineGo to article: BEA TechnologiesGo to article: MyonexGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Single Use SupportGo to article: SkyepharmaGo to article: In DataGo to article: Cloud hiring effortsGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue